News Releases

Date Title and Summary Additional Formats
Toggle Summary ChemoCentryx Awarded $14 Million NIH Grant to Develop Chemokine-Based Immunomodulators
ChemoCentryx Awarded $14 Million NIH Grant to Develop Chemokine-Based Immunomodulators October 13, 2003; San Carlos, Calif. — ChemoCentryx, Inc. today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded the company
View HTML
Toggle Summary ChemoCentryx Announces Initiation of Phase I Clinical Trial of T487 by Tularik
Novel Oral Anti-inflammatory Selected from Rich Drug Portfolio Targeting Chemokine System
View HTML